Haoyuan Pharmaceutical plans to purchase 100%equity of drug source drugs

"Science and Technology Board Daily" September 6 news, Shanghai Haoyuan Pharmaceutical Co., Ltd. announced that the company plans to purchase Wangyuan (Wang Yuan), Shanghai Yuanmeng, Shanghai Yuanli and Ningbo Jiusheng holding through the issuance of shares and payment cash. 100%equity of the medicine source drugs, as well as the supporting funds raised by the company's controlling shareholder Anyi Information Issuing shares of not more than 50 million yuan. Considering the impact of the new crown epidemic, the transaction price of 100%equity of the medicine source drugs was adjusted from 420 million yuan to 410 million yuan. In 2022, the net profit was reduced by 5 million yuan. It was 79 million yuan.

According to the company's information, Shanghai Haoyuan Pharmaceutical Co., Ltd. was established in 2006. It is located in Zhangjiang Biomedical Base in Shanghai. The development and production technology improvement of the body is a high -tech enterprise provided related products and technical services for global pharmaceutical companies and scientific research institutions to provide related products and technical services from drug discovery to the large -scale production of raw materials and pharmaceutical intermediates. The company has won a number of honorary titles such as Shanghai's "specialized new" enterprise, Shanghai little giant enterprise, Shanghai brand cultivation demonstration enterprise, Shanghai patent work pilot enterprise, and Pudong New District enterprise R & D institution.

Haoyuan Pharmaceutical focuses on the field of biomedicine, and has formed a development platform including high -active material drug (HPAPI) development platform, multi -handed complex drug technology platform, vitamin D derivatives, and drug development platform, special targeted drug development platform, pharmaceutical solid -state chemistry research research The technical platform, molecular block and tool compound library development and incubation platform, including the development and incubation platform, has 6 core technology platforms. The service scope covers the treatment fields such as antitumor, antiviral, diabetes, cardiovascular and cerebrovascular, immune systems, and nervous systems. The company has established a kg -class GMP condition laboratory and pharmaceutical research and development center, and has established a business center in Hong Kong and the United States.

Smart bud data shows that Shanghai Haoyuan Pharmaceutical Co., Ltd. and its related companies have applied for nearly 140 patents, of which 90 invention patents, accounting for more than 65%. By further analyzing its patented technology data, the company's patented technology is mainly deployed in the fields of compounds, intermediates, organic solvents, inhibitors and other fields.

- END -